The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B

Inclusion Criteria

   1. Patient was symptomatic from his/her aortic valve stenosis, as demonstrated by NYHA
   Functional Class II or greater.

   2. The probability of death or serious, irreversible morbidity is greater than or equal
   to 50%.

   3. The heart team agreed (and verified in the case review process) that valve
   implantation would likely benefit the patient.

   4. The study patient or the study patient's legal representative was informed of the
   nature of the study, agreed to its provisions and had provided written informed
   consent as approved by the Institutional Review Board (IRB) of the respective clinical
   site.

   5. The study patient agreed to comply with all required post-procedure follow-up visits
   including annual visits through 5 years and analysis close date visits, which was
   conducted as a phone follow-up.

Exclusion Criteria

   1. Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is
   non-calcified.

   2. Significant aortic disease, including marked tortuosity (hyperacute bend), aortic arch
   atheroma [especially if thick (> 5 mm), protruding or ulcerated] or narrowing
   (especially with calcification and surface irregularities) of the abdominal or
   thoracic aorta, severe "unfolding" and tortuosity of the thoracic aorta.
   (Transfemoral)

   3. Currently participating in an investigational drug or another device study. Note:
   Trials requiring extended follow-up for products that were investigational, but have
   since become commercially available, are not considered investigational trials.

   4. It is known that the patient is currently enrolled in the PARTNER I Trial or was
   withdrawn from the PARTNER I Trial prior to endpoint analysis.

   5. Active bacterial endocarditis within 6 months (180 days) of procedure.